Paul Sargos, MD, of the Institut Bergonié, discusses phase III findings from the GETUG-AFU 17 study, which compared adjuvant vs early salvage radiotherapy, both combined with short-term androgen-deprivation therapy after radical prostatectomy for localized prostate cancer. Although lacking statistical power, the study showed no benefit in event-free survival for adjuvant compared to salvage radiotherapy (Abstract 33).
Vinai Gondi, MD, of Northwestern Medicine Cancer Center and Northwestern Medicine Proton Center, discusses the preliminary results of an NRG Oncology study of radiotherapy do...
Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-fie...
Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and t...
Alphonse G. Taghian, MD, PhD, of Massachusetts General Hospital, reviews the 10-year follow-up of a dose-escalation trial studying accelerated partial-breast irradiation and ...
Juliane Hörner-Rieber, MD, of Heidelberg University Hospital, discusses phase III results of the MINT trial, which showed that conventionally fractionated intensity-modulated...